Biotech Values

[DewDiligence]

Thanks for the ITMN CC notes. A point I forgot to mention in #msg-40319474 is that ITMN itself—rather than Roche—is conducting the ITMN-191 testing with ritonavir. This might mean that Roche is not fully on board with the idea. It could also mean that ITMN is hedging its bets with respect to ITMN-191 co-formulation in case Roche eventually decides not to back the all-oral approach to HCV. A more benign interpretation is that ITMN is performing the phase-1 work with ritonavir because it is ITMN’s job under the terms of the Roche partnership to do phase-1 testing.

I’m surprised that no analyst asked about this wrinkle on the CC.